Payment overview · 2025
General Payments
$73,030.81
139 reported records · 29 companies
Healthcare provider profile · identity verified
Alexander Barsouk, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · PITTSBURGH, PA · NPI 1114929544
Verified facts
What the public records show
CMS Open Payments records show Alexander Barsouk, MD received $73,030.81 in general payments during 2025 across 139 reported records.
E.R. Squibb & Sons, L.L.C. accounted for 70.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 59 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Brukinsa, Imfinzi, Jakafi, Reblozyl, Xtandi.
ARRAY BIOPHARMA INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XTANDI as an associated drug or biological on 98 records involving 88 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Xtandi by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IMFINZI as an associated drug or biological on 14406 records involving 6935 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Imfinzi by this doctor in 2024.
BeOne Medicines USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRUKINSA as an associated drug or biological on 10251 records involving 4941 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Brukinsa by this doctor in 2024.
BeiGene USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRUKINSA as an associated drug or biological on 2084 records involving 1673 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Brukinsa by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Eliquis by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REBLOZYL as an associated drug or biological on 17361 records involving 5696 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Reblozyl by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Eliquis by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REBLOZYL as an associated drug or biological on 1732 records involving 943 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Reblozyl by this doctor in 2024.
Incyte Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JAKAFI as an associated drug or biological on 14854 records involving 6477 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Jakafi by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Xarelto by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REBLOZYL as an associated drug or biological on 1175 records involving 979 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Reblozyl by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XTANDI as an associated drug or biological on 19368 records involving 7657 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Xtandi by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $51,496.85 | 70.5% | 32 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $4,349.13 | 6.0% | 20 | 2025 |
| BeiGene USA, Inc. | Unresolved — no canonical attribution shown | $4,123.98 | 5.7% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $3,991.25 | 5.5% | 13 | 2025 |
| AVYXA PHARMA, LLC | Unresolved — no canonical attribution shown | $3,368.70 | 4.6% | 7 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $2,162.90 | 3.0% | 4 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $1,334.70 | 1.8% | 4 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $1,122.08 | 1.5% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $186.57 | 0.3% | 7 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $110.17 | 0.1% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $82.19 | 0.1% | 4 | 2025 |
| Exelixis Inc. | Unresolved — no canonical attribution shown | $67.33 | 0.1% | 2 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $65.47 | 0.1% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $65.06 | 0.1% | 3 | 2025 |
| Stemline Therapeutics Inc. | Unresolved — no canonical attribution shown | $62.74 | 0.1% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $51.17 | 0.1% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $50.28 | 0.1% | 2 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $47.85 | 0.1% | 2 | 2025 |
| Acrotech Biopharma Inc. | Unresolved — no canonical attribution shown | $43.01 | 0.1% | 2 | 2025 |
| Geron Corporation | Unresolved — no canonical attribution shown | $42.83 | 0.1% | 2 | 2025 |
| Aveo Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.61 | 0.1% | 2 | 2025 |
| BeOne Medicines USA, Inc. | Unresolved — no canonical attribution shown | $32.34 | 0.0% | 2 | 2025 |
| Rigel Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.89 | 0.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.39 | 0.0% | 1 | 2025 |
| ADC THERAPEUTICS AMERICA, INC. | Unresolved — no canonical attribution shown | $21.27 | 0.0% | 1 | 2025 |
| Genmab U.S., Inc. | Unresolved — no canonical attribution shown | $19.23 | 0.0% | 1 | 2025 |
| ARRAY BIOPHARMA INC | Unresolved — no canonical attribution shown | $18.30 | 0.0% | 2 | 2025 |
| TAIHO ONCOLOGY, INC. | Unresolved — no canonical attribution shown | $17.07 | 0.0% | 1 | 2025 |
| Deciphera Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.45 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $49,208.00 | 9 |
| Consulting Fee | $16,217.50 | 10 |
| Travel and Lodging | $4,692.70 | 13 |
| Food and Beverage | $2,912.61 | 107 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OPDIVO Normalized: opdivo |
Biological | Celgene Corporation, E.R. Squibb & Sons, L.L.C. | $41,984.23 | 29 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $4,124.61 | 7 | 2025 |
Source payment records
|
|||||
| BRUKINSA Normalized: brukinsa |
Drug | BeiGene USA, Inc. | $4,123.98 | 6 | 2025 |
Source payment records
|
|||||
| TIVDAK Normalized: tivdak |
Biological | PFIZER INC. | $3,822.87 | 2 | 2025 |
Source payment records
|
|||||
| FRUZAQLA Normalized: fruzaqla |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $2,145.72 | 3 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Biotech, Inc. | $1,289.00 | 2 | 2025 |
Source payment records
|
|||||
| Enhertu Normalized: enhertu |
Drug | Daiichi Sankyo Inc. | $130.88 | 8 | 2025 |
Source payment records
|
|||||
| KISQALI Normalized: kisqali |
Drug | Novartis Pharmaceuticals Corporation | $109.91 | 4 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $85.18 | 4 | 2025 |
Source payment records
|
|||||
| ORGOVYX Normalized: orgovyx |
Drug | PFIZER INC., Sumitomo Pharma America, Inc. | $68.47 | 4 | 2025 |
Source payment records
|
|||||
| CABOMETYX Normalized: cabometyx |
Drug | Exelixis Inc. | $67.33 | 2 | 2025 |
Source payment records
|
|||||
| SCEMBLIX Normalized: scemblix |
Drug | Novartis Pharmaceuticals Corporation | $67.25 | 2 | 2025 |
Source payment records
|
|||||
| Orserdu Normalized: orserdu |
Drug | Stemline Therapeutics Inc. | $62.74 | 3 | 2025 |
Source payment records
|
|||||
| Vanflyta Normalized: vanflyta |
Drug | Daiichi Sankyo Inc. | $57.83 | 2 | 2025 |
Source payment records
|
|||||
| PADCEV Normalized: padcev |
Biological | PFIZER INC. | $56.94 | 3 | 2025 |
Source payment records
|
|||||
| ADCETRIS Normalized: adcetris |
Biological | PFIZER INC. | $52.33 | 3 | 2025 |
Source payment records
|
|||||
| ELREXFIO Normalized: elrexfio |
Drug | PFIZER INC. | $52.33 | 3 | 2025 |
Source payment records
|
|||||
| Lenvima Normalized: lenvima |
Drug | Eisai Inc. | $50.28 | 2 | 2025 |
Source payment records
|
|||||
| RYBREVANT Normalized: rybrevant |
Drug | Janssen Biotech, Inc. | $45.70 | 2 | 2025 |
Source payment records
|
|||||
| REBLOZYL Normalized: reblozyl |
Biological | Celgene Corporation, Merck Sharp & Dohme LLC | $43.15 | 2 | 2025 |
Source payment records
|
|||||
| BELEODAQ Normalized: beleodaq |
Drug | Acrotech Biopharma Inc. | $43.01 | 2 | 2025 |
Source payment records
|
|||||
| RYTELO Normalized: rytelo |
Drug | Geron Corporation | $42.83 | 2 | 2025 |
Source payment records
|
|||||
| FOTIVDA Normalized: fotivda |
Drug | Aveo Pharmaceuticals, Inc. | $37.61 | 2 | 2025 |
Source payment records
|
|||||
| DATROWAY Normalized: datroway |
Drug | Daiichi Sankyo Inc. | $35.81 | 3 | 2025 |
Source payment records
|
|||||
| IBRANCE Normalized: ibrance |
Drug | PFIZER INC. | $32.63 | 2 | 2025 |
Source payment records
|
|||||
| TUKYSA Normalized: tukysa |
Drug | PFIZER INC. | $32.63 | 2 | 2025 |
Source payment records
|
|||||
| TEVIMBRA Normalized: tevimbra |
Drug | BeOne Medicines USA, Inc. | $32.34 | 2 | 2025 |
Source payment records
|
|||||
| JEMPERLI Normalized: jemperli |
Biological | GlaxoSmithKline, LLC. | $31.18 | 2 | 2025 |
Source payment records
|
|||||
| ZEJULA Normalized: zejula |
Drug | GlaxoSmithKline, LLC. | $31.18 | 2 | 2025 |
Source payment records
|
|||||
| WELIREG Normalized: welireg |
Drug | Merck Sharp & Dohme LLC | $29.53 | 1 | 2025 |
Source payment records
|
|||||
| XTANDI Normalized: xtandi |
Drug | PFIZER INC. | $26.48 | 3 | 2025 |
Source payment records
|
|||||
| IMFINZI Normalized: imfinzi |
Biological | AstraZeneca Pharmaceuticals LP | $26.37 | 1 | 2025 |
Source payment records
|
|||||
| BLENREP Normalized: blenrep |
Biological | GlaxoSmithKline, LLC. | $25.85 | 1 | 2025 |
Source payment records
|
|||||
| Onivyde Normalized: onivyde |
Drug | Ipsen Biopharmaceuticals, Inc | $25.65 | 1 | 2025 |
Source payment records
|
|||||
| OJJAARA Normalized: ojjaara |
Drug | GlaxoSmithKline, LLC. | $25.16 | 1 | 2025 |
Source payment records
|
|||||
| LYNPARZA Normalized: lynparza |
Biological | Merck Sharp & Dohme LLC | $24.99 | 1 | 2025 |
Source payment records
|
|||||
| Gavreto Normalized: gavreto |
Drug | Rigel Pharmaceuticals, Inc. | $22.89 | 1 | 2025 |
Source payment records
|
|||||
| Rezlidhia Normalized: rezlidhia |
Drug | Rigel Pharmaceuticals, Inc. | $22.89 | 1 | 2025 |
Source payment records
|
|||||
| TAVALISSE Normalized: tavalisse |
Drug | Rigel Pharmaceuticals, Inc. | $22.89 | 1 | 2025 |
Source payment records
|
|||||
| JAYPIRCA Normalized: jaypirca |
Drug | Lilly USA, LLC | $22.39 | 1 | 2025 |
Source payment records
|
|||||
| RETEVMO Normalized: retevmo |
Drug | Lilly USA, LLC | $22.39 | 1 | 2025 |
Source payment records
|
|||||
| VERZENIO Normalized: verzenio |
Drug | Lilly USA, LLC | $22.39 | 1 | 2025 |
Source payment records
|
|||||
| Tazverik Normalized: tazverik |
Drug | Ipsen Biopharmaceuticals, Inc | $22.20 | 1 | 2025 |
Source payment records
|
|||||
| JAKAFI Normalized: jakafi |
Drug | Incyte Corporation | $22.08 | 2 | 2025 |
Source payment records
|
|||||
| NIKTIMVO Normalized: niktimvo |
Drug | Incyte Corporation | $22.08 | 2 | 2025 |
Source payment records
|
|||||
| ZYNLONTA Normalized: zynlonta |
Drug | ADC THERAPEUTICS AMERICA, INC. | $21.27 | 1 | 2025 |
Source payment records
|
|||||
| KEYTRUDA QLEX Normalized: keytruda qlex |
Biological | Merck Sharp & Dohme LLC | $20.07 | 1 | 2025 |
Source payment records
|
|||||
| Epkinly Normalized: epkinly |
Drug | Genmab U.S., Inc. | $19.23 | 1 | 2025 |
Source payment records
|
|||||
| BRAFTOVI Normalized: braftovi |
Drug | ARRAY BIOPHARMA INC | $18.30 | 2 | 2025 |
Source payment records
|
|||||
| LORBRENA Normalized: lorbrena |
Drug | ARRAY BIOPHARMA INC | $18.30 | 2 | 2025 |
Source payment records
|
|||||
| MEKTOVI Normalized: mektovi |
Drug | ARRAY BIOPHARMA INC | $18.30 | 2 | 2025 |
Source payment records
|
|||||
| TALZENNA Normalized: talzenna |
Drug | PFIZER INC. | $17.30 | 2 | 2025 |
Source payment records
|
|||||
| ICLUSIG Normalized: iclusig |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $17.18 | 1 | 2025 |
Source payment records
|
|||||
| INQOVI Normalized: inqovi |
Drug | TAIHO ONCOLOGY, INC. | $17.07 | 1 | 2025 |
Source payment records
|
|||||
| LONSURF Normalized: lonsurf |
Drug | TAIHO ONCOLOGY, INC. | $17.07 | 1 | 2025 |
Source payment records
|
|||||
| QINLOCK Normalized: qinlock |
Drug | Deciphera Pharmaceuticals Inc. | $15.45 | 1 | 2025 |
Source payment records
|
|||||
| ROMVIMZA Normalized: romvimza |
Drug | Deciphera Pharmaceuticals Inc. | $15.45 | 1 | 2025 |
Source payment records
|
|||||
| INLYTA Normalized: inlyta |
Drug | PFIZER INC. | $15.29 | 1 | 2025 |
Source payment records
|
|||||
| PLUVICTO Normalized: pluvicto |
Drug | Novartis Pharmaceuticals Corporation | $9.41 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BRUKINSA brukinsa |
2025 | Brukinsa | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| IMFINZI imfinzi |
2025 | Imfinzi | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JAKAFI jakafi |
2025 | Jakafi | 2024 | 58 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REBLOZYL reblozyl |
2025 | Reblozyl | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XTANDI xtandi |
2025 | Xtandi | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ARRAY BIOPHARMA INC Exact reporting entity; no affiliate inference |
2025 | XTANDI open payments reported associated product |
CMS Open Payments — General Payments 98 supporting records · 88 recipient NPIs · example record 1228800820 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | IMFINZI open payments reported associated product |
CMS Open Payments — General Payments 14406 supporting records · 6935 recipient NPIs · example record 1206131578 |
Imfinzi · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| BeOne Medicines USA, Inc. Exact reporting entity; no affiliate inference |
2025 | BRUKINSA open payments reported associated product |
CMS Open Payments — General Payments 10251 supporting records · 4941 recipient NPIs · example record 1202883638 |
Brukinsa · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| BeiGene USA, Inc. Exact reporting entity; no affiliate inference |
2025 | BRUKINSA open payments reported associated product |
CMS Open Payments — General Payments 2084 supporting records · 1673 recipient NPIs · example record 1202877750 |
Brukinsa · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
88 | 18 |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | REBLOZYL open payments reported associated product |
CMS Open Payments — General Payments 17361 supporting records · 5696 recipient NPIs · example record 1184377709 |
Reblozyl · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
88 | 18 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | REBLOZYL open payments reported associated product |
CMS Open Payments — General Payments 1732 supporting records · 943 recipient NPIs · example record 1184377805 |
Reblozyl · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Incyte Corporation Exact reporting entity; no affiliate inference |
2025 | JAKAFI open payments reported associated product |
CMS Open Payments — General Payments 14854 supporting records · 6477 recipient NPIs · example record 1225959940 |
Jakafi · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
56 | 11 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | REBLOZYL open payments reported associated product |
CMS Open Payments — General Payments 1175 supporting records · 979 recipient NPIs · example record 1237992280 |
Reblozyl · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
88 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | XTANDI open payments reported associated product |
CMS Open Payments — General Payments 19368 supporting records · 7657 recipient NPIs · example record 1228794230 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Anastrozole | Anastrozole | 124 | 22 |
| Hydroxyurea | Hydroxyurea | 113 | 20 |
| Eliquis | Apixaban | 88 | 18 |
| Acyclovir | Acyclovir | 58 | 13 |
| Jakafi | Ruxolitinib Phosphate | 58 | suppressed |
| Dexamethasone | Dexamethasone | 56 | 26 |
| Xarelto | Rivaroxaban | 56 | 11 |
| Letrozole | Letrozole | 53 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 51 | 32 |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 48 | 28 |
| Allopurinol | Allopurinol | 43 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 42 | 11 |
| Anagrelide Hcl | Anagrelide Hcl | 35 | suppressed |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 31 | suppressed |
| Lenalidomide | Lenalidomide | 29 | suppressed |
| Prednisone | Prednisone | 29 | 13 |
| Imatinib Mesylate | Imatinib Mesylate | 27 | suppressed |
| Darzalex Faspro | Daratumumab-Hyaluronidase-Fihj | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl/Pf | 22 | suppressed |
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosp/Pf | 21 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 20 | suppressed |
| Inflectra | Infliximab-Dyyb | 19 | suppressed |
| Palonosetron Hcl | Palonosetron Hcl | 19 | suppressed |
| Imfinzi | Durvalumab | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Brukinsa | Zanubrutinib | 15 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 13 | suppressed |
| Reblozyl | Luspatercept-Aamt | 13 | suppressed |
| Xtandi | Enzalutamide | 13 | suppressed |
| Gemcitabine Hcl | Gemcitabine Hcl | 12 | suppressed |
| Potassium Chloride | Potassium Chloride | 12 | suppressed |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $73,030.81 · 139 records | E.R. Squibb & Sons, L.L.C. | ADCETRIS, BELEODAQ, BLENREP, BRAFTOVI, BRUKINSA, CABOMETYX, DATROWAY, ELREXFIO, ERLEADA, Enhertu, Epkinly, FOTIVDA, FRUZAQLA, Gavreto, IBRANCE, ICLUSIG, IMFINZI, INJECTAFER, INLYTA, INQOVI, JAKAFI, JAYPIRCA, JEMPERLI, KEYTRUDA, KEYTRUDA QLEX, KISQALI, LONSURF, LORBRENA, LYNPARZA, Lenvima, MEKTOVI, NIKTIMVO, OJJAARA, OPDIVO, ORGOVYX, Onivyde, Orserdu, PADCEV, PLUVICTO, QINLOCK, REBLOZYL, RETEVMO, ROMVIMZA, RYBREVANT, RYTELO, Rezlidhia, SCEMBLIX, TALZENNA, TAVALISSE, TEVIMBRA, TIVDAK, TUKYSA, Tazverik, VERZENIO, Vanflyta, WELIREG, XTANDI, ZEJULA, ZYNLONTA | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Brukinsa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ARRAY BIOPHARMA INC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error